Oriel Therapeutics, a specialty pharma concentrated on respiratory care, has appointed Richard Fuller as CEO, effective immediately. Fuller was formerly a senior executive at GlaxoSmithKline, and was most recently executive vice president of research and development at Aerovance.
TheraGenetics Limited, a personalized medicine diagnostics company, has appointed Robert McBurney to executive vice president. McBurney will report to Richard Kivel, CEO of TheraGenetics.
Curemark, a biotech focused on the treatment of neurological and other diseases, has appointed Elisa Zinberg as vice president of operations. Zinberg was previously COO of The Masters Circle, a health care consulting company.